New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand Novo Nordisk has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points against heavyweight ...

Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster market share

Tracy Staton Novo Nordisk finally launched its next-gen diabetes treatment Tresiba in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes ...

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Eric Palmer Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($ 78.1 million) plant to produce its FlexPen prefilled devices to better ...

UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.

Eric Palmer With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $ 2 billion on its first API plant in the U.S., ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

Novo says new U.S. plant may be best bet to offset the FX bite

Eric Palmer Novo Nordisk has forecast that currency hedging losses will leave it with an $ 850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have ...

Novo Nordisk ties the R&D knot with Genmab, and they’re not focused on cancer

John Carroll Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs–and this time the Danish biotech company will not be focused ...

Novo Nordisk launches diabetes ‘dream team’ contest with NBA star as a prize

Carly Helfand Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling ...

Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month

Tracy Staton Novo Nordisk says its new drug Saxenda has a niche in the U.S. obesity market. Now, the Danish drugmaker has the chance to prove it. Saxenda is rolling out ...

Novo Nordisk’s game-changing oral diabetes drug clears Phase II

Damian Garde Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field. FierceBiotech ...
Page 1 of 41234
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS